Drug Profile


Alternative Names: Ajaduo; BI 10773/BI 1356; BI 10773/linagliptin; BI 1356/BI 10773; BI 1356/empagliflozin; Empa/Lina FDC; Empagliflozin/BI 1356; Glyxambi; Linagliptin/BI 10773; Linagliptin/empagliflozin

Latest Information Update: 16 Jul 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Boehringer Ingelheim
  • Developer Boehringer Ingelheim; Eli Lilly
  • Class Alkynes; Antihyperglycaemics; Piperidines; Purines; Quinazolines; Small molecules
  • Mechanism of Action CD26 antigen inhibitors; Sodium-glucose transporter 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Type 2 diabetes mellitus

Most Recent Events

  • 11 Jul 2018 Boehringer Ingelheim and Lupin agree to market empagliflozin/linagliptin in India for Type-2 diabetes mellitus
  • 02 Jul 2018 CHMP issues positive opinion to expand the empagliflozin/ linagliptin label to include positive effects on cardiovascular and renal outcomes in European Union
  • 16 Jun 2017 Boehringer Ingelheim and Eli Lilly completes a phase III trial in Type-2 diabetes mellitus in Japan (NCT02489968)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top